Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin in XIAP Deficiency
NCT07433621Phase 1Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2026
- Primary completion
- Nov 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quercetin in X-linked inhibitor of apoptosis protein deficiency, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Safety of quercetin at 6 months and Tolerability of quercetin at 6 months. Started Feb 2026; status: recruiting.
02
Drugs
quercetin
03
Conditions
X-linked inhibitor of apoptosis protein deficiency
Beyond the preview
Go deeper on NCT07433621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433621.